Urogen Pharma (NASDAQ:URGN) Given Consensus Rating of “Moderate Buy” by Analysts

Urogen Pharma (NASDAQ:URGN) has been assigned an average recommendation of “Moderate Buy” from the eight research firms that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating on the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $33.2857.

A number of analysts recently weighed in on the stock. D. Boral Capital reaffirmed a “buy” rating and set a $33.00 price target on shares of Urogen Pharma in a research report on Friday, January 23rd. Wall Street Zen upgraded Urogen Pharma from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Urogen Pharma in a research report on Wednesday, January 21st.

Urogen Pharma Stock Up 2.5%

URGN opened at $21.70 on Friday. Urogen Pharma has a 52-week low of $3.42 and a 52-week high of $30.00. The company has a 50 day moving average of $21.28 and a two-hundred day moving average of $20.88. The company has a market cap of $1.02 billion, a P/E ratio of -6.27 and a beta of 1.32.

Insiders Place Their Bets

In other Urogen Pharma news, insider Mark Schoenberg sold 7,373 shares of the business’s stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $19.69, for a total value of $145,174.37. Following the transaction, the insider owned 144,985 shares in the company, valued at $2,854,754.65. The trade was a 4.84% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, General Counsel Jason Drew Smith sold 7,479 shares of the company’s stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $19.69, for a total transaction of $147,261.51. Following the completion of the transaction, the general counsel directly owned 51,326 shares of the company’s stock, valued at approximately $1,010,608.94. The trade was a 12.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 4.70% of the company’s stock.

Institutional Trading of Urogen Pharma

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Osaic Holdings Inc. grew its stake in Urogen Pharma by 491.2% during the 2nd quarter. Osaic Holdings Inc. now owns 3,695 shares of the company’s stock valued at $50,000 after purchasing an additional 3,070 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in Urogen Pharma by 27.2% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,275 shares of the company’s stock valued at $53,000 after acquiring an additional 486 shares during the last quarter. State of Wyoming acquired a new position in Urogen Pharma during the 3rd quarter worth $66,000. Russell Investments Group Ltd. increased its position in shares of Urogen Pharma by 1,594.4% in the 3rd quarter. Russell Investments Group Ltd. now owns 3,321 shares of the company’s stock worth $66,000 after purchasing an additional 3,125 shares during the last quarter. Finally, Strs Ohio acquired a new stake in shares of Urogen Pharma in the 3rd quarter valued at about $76,000. 91.29% of the stock is owned by hedge funds and other institutional investors.

About Urogen Pharma

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.